Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B
2023 · New England Journal of Medicine · 314 citations
https://doi.org/10.1056/nejmoa2211644
M
Michael Recht
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
255
Papers
7.8K
Citations
40
h-index
97
i10-index
Michael Recht is an academic researcher from National Kidney Foundation. The author has contributed to research in topics: Hemophilia Treatment and Research & Platelet Disorders and Treatments & Blood Coagulation and Thrombosis Mechanisms. The author has an h-index of 40, co-authored 217 publications.
ORCID: 0000-0002-2805-1016Papers by this author
worksMultiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A
2021 · New England Journal of Medicine · 234 citations
https://doi.org/10.1056/nejmoa2104205
A human 15-kDa IFN-induced protein induces the secretion of IFN-gamma
1991 · The Journal of Immunology · 179 citations
https://doi.org/10.4049/jimmunol.147.8.2617
Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B
2019 · Blood Advances · 128 citations
https://doi.org/10.1182/bloodadvances.2019000811
Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity
2015 · Journal of Thrombosis and Haemostasis · 59 citations
https://doi.org/10.1111/jth.13141
Stable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy
2022 · Blood Advances · 56 citations
https://doi.org/10.1182/bloodadvances.2022008886
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat